atHeart Medical has commenced operations

atHeart Medical announced today that it has commenced operations and is initiating its U.S. Investigational Device Exemption (IDE) trial.

Beginning with a purpose

I couldn’t be more enthusiastic about our purpose at atHeart Medical: allowing more future options for patients with atrial septal defects (ASDs) by reducing device footprint.…

April 20, 2021

atHeart Medical has commenced operations and is initiating its U.S. IDE trial.
atHeart Medical announced today that it has commenced operations and is initiating its U.S. Investigational Device Exemption (IDE) trial Read more

Sigler M, Söderberg B, Schmitt B, Mellmann A, Bernhard J. Carag bioresorbable septal occluder (CBSO): histopathology of experimental implants. EuroIntervention. 2018 Feb 20;13(14):1655-1661 Read more